premise: The large, late-stage Phase 3 trial of melanoma patients was testing whether combining Merck's blockbuster immunotherapy, <hypo>, , known as an IDO inhibitor.
hypothesis: <hypo> should be "Keytruda, would have helped more patients in the scheme of things"